the truth

This is how I see Metabolic.
Currently we own a company that has one less string to its bow. Instead of curing a fat gut we will be curing thinning bones and potential fractures, curvature of the spine etc. The shares when they were issued were 20 cents. The market then was a multibillion dollar market, and now it is still a multibillion dollar market. When it was issued it was a one horse company and now it has a herd of drugs. The potential market is the same, but there are more opportunities of achieving that result. The drug was a flop and we all knew that risk. I don't believe we were given the full risk details, which is why Monash Uni sold out early. If you were to buy into a company now with approx 5 years plus of data in research, a string of product pipeline, and potential of making billions of dollars annually, you would be looking at an issue price of more than 20 cents. The drug has already got a proven track record of safety, and tolerability, and will come to the market (if it works) no more than a year later than the fat drug. If the pain drug works it will be another bonus, and the product pipeline which we will see announced next week, will make the shares worth at least 20cents. The company needs to get rid of Chris Bellyache, and the rest of the board for that matter to appease a very disillusioned market. It will be interesting to see who has dumped the shares. I’m holding at least for the moment so I have enough shares to get rid of Chris Bellyache. If the board isn’t totally dismantled or culled, I will look to sell down but at the moment I don’t see any need to sell. Nothing has really changed except the company will take a lot longer to make money. Why would I want to lose hundreds of thousands of dollars if I don’t need to? The company’s handling of the whole fiasco, and the poxy setup of the trial results mean heads must roll and fast.
Bye Chris.
Too many mistakes I want your resignation this week coming.